Over the course of the COVID-19 pandemic, information has varied around whether or not – and how severely – children are affected by the virus.
In this episode for our Coronavirus Special Edition Series, Pierre Omnes, Executive Director, SSU and Regulatory and Alex Cvetkovich Muntañola, MD, Executive Director, Clinical Development at Syneos Health, share what we’ve learned so far about the impact of COVID-19 on children’s health, and how approaches to clinical trials for this specific population have been altered.
Stay tuned for more installments of the Coronavirus Special Edition Series, which explores, from an operational standpoint, the impact of COVID-19 on the biopharma industry, the challenges for rapid R&D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues. Additional materials and insights can also be found in our COVID-19 Resource Center.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.
